SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the completion of its previously announced acquisition of Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58 for the treatment of classical homocystinuria (HCU). Read the press release >
https://travere.com/wp-content/uploads/Retrophin-Solo-full-color.png386395superadminhttps://travere.com/wp-content/uploads/Travere-TxTM_Inline-fullcolor.pngsuperadmin2020-11-12 17:00:502020-11-14 17:31:18Retrophin Completes Acquisition of Orphan Technologies
Author, composer and life-long learner, Matthew lives with peroxisome biogenesis disorder-Zellweger spectrum disorder (PBD-ZSD).
https://travere.com/wp-content/uploads/Matthew.jpg7521164clienthttps://travere.com/wp-content/uploads/Travere-TxTM_Inline-fullcolor.pngclient2020-01-17 15:56:182020-10-21 15:18:07Meet Matthew
At the 2019 ERA-EDTA Congress in Budapest, the company hosted a panel discussion led by people living with rare glomerular disease. Lindsay, a 17-year-old scholar, athlete and musician, shared about her journey with focal segmental glomerulosclerosis (FSGS).
SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today reported its third quarter 2020 financial results and provided a corporate update. Read the press release >
https://travere.com/wp-content/uploads/Retrophin-Solo-full-color.png386395superadminhttps://travere.com/wp-content/uploads/Travere-TxTM_Inline-fullcolor.pngsuperadmin2019-11-05 11:30:512020-11-10 11:55:56Retrophin Reports Third Quarter 2020 Financial Results
SAN DIEGO, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it has entered into a definitive agreement to acquire Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58 for the treatment of classical homocystinuria (HCU). Read the press release >
https://travere.com/wp-content/uploads/Retrophin-Solo-full-color.png386395superadminhttps://travere.com/wp-content/uploads/Travere-TxTM_Inline-fullcolor.pngsuperadmin2020-10-22 09:25:312020-11-10 11:41:14Retrophin Announces Agreement to Acquire Orphan Technologies
SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with focal segmental glomerulosclerosis (FSGS) that achieved complete remission of proteinuria in the Phase 2 DUET Study, at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined. Read the press release >
https://travere.com/wp-content/uploads/Retrophin-Solo-full-color.png386395superadminhttps://travere.com/wp-content/uploads/Travere-TxTM_Inline-fullcolor.pngsuperadmin2020-10-09 11:44:212020-11-10 12:25:51Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined
On Rare Disease Day 2019, our team had the honor of speaking with Grace Whiting, president and chief executive officer of the National Alliance for Caregiving. Her compassion and professional energy to help caregivers is profound. We present the unedited words Grace shared with us here.
https://travere.com/wp-content/uploads/grace_lg.jpg7521164David Andersonhttps://travere.com/wp-content/uploads/Travere-TxTM_Inline-fullcolor.pngDavid Anderson2020-10-28 15:49:292020-11-11 19:54:52Grace Whiting on Caregiving
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety and efficacy of sparsentan in IgA nephropathy (IgAN). Read the press release >
https://travere.com/wp-content/uploads/Retrophin-Solo-full-color.png386395superadminhttps://travere.com/wp-content/uploads/Travere-TxTM_Inline-fullcolor.pngsuperadmin2020-09-23 14:08:572020-09-30 14:38:20Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
August 12, 2020 - the Black Women’s Health Imperative hosted a national webinar with its partner, the National Coalition of 100 Black Women, Inc. entitled “Our Health, Our Community: Mobilizing for the Survival of Black Women,” in partnership with EBONY.
https://travere.com/wp-content/uploads/Black-Womens-Health-Imperative-Logo.png240500superadminhttps://travere.com/wp-content/uploads/Travere-TxTM_Inline-fullcolor.pngsuperadmin2020-09-22 09:56:592020-10-16 12:09:16Eric Dube, Ph.D., Speaks at Black Women’s Health Imperative Event
SAN DIEGO (August 3, 2020) – Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., president and chief executive officer, has been named by PharmaVOICE magazine to the 2020 PharmaVOICE 100 – an award that recognizes the 100 Most Inspiring People in the life sciences industry. Read the press release >
https://travere.com/wp-content/uploads/PV100-300x228-1.png228300superadminhttps://travere.com/wp-content/uploads/Travere-TxTM_Inline-fullcolor.pngsuperadmin2020-08-03 12:41:422020-09-29 12:27:54Retrophin President and Chief Executive Officer Eric Dube Named to the 2020 PharmaVOICE 100
Retrophin Completes Acquisition of Orphan Technologies
NewsMeet Matthew
Stories & InsightsMeet Lindsey
Stories & InsightsRetrophin Reports Third Quarter 2020 Financial Results
NewsRetrophin Announces Agreement to Acquire Orphan Technologies
NewsRetrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined
NewsGrace Whiting on Caregiving
Advocacy, Stories & InsightsRetrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
NewsEric Dube, Ph.D., Speaks at Black Women’s Health Imperative Event
NewsRetrophin President and Chief Executive Officer Eric Dube Named to the 2020 PharmaVOICE 100
News